Skip to main content
. 2018 Jul 31;35(8):1140–1152. doi: 10.1007/s12325-018-0753-6

Fig. 1.

Fig. 1

Evaluation of disease control in a. Patients with asthma or ACO (n = 720) and b. Patients with COPD or ACO (n = 876) following 12 weeks’ treatment with Bufomix Easyhaler®. a Patients with asthma or ACO (n = 720). b Patients with COPD or ACO (n = 876). ACO asthma-COPD overlap, ACT asthma control test, CAT COPD assessment test, COPD chronic obstructive pulmonary disease